Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.dnagenotek.com
Number of Employees: 60
Year Founded: 1998
Total Amount Raised (CAD mm)†: 1.40
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
DNA Genotek Inc. provides biological sample collection, stabilization, and preparation products for health research institutes. The company provides human products, such as human genomics collection kits, such as DNA collection kits, and RNA collection kits, microbiome collection kits, infectious disease collection kits, animal collection kits, stabilization reagents, and preparation reagents, and animal products, which include DNA collection kits and preparation reagents. It also offers mailing accessories, and accessories for assisted collection, and various customization options, such as branding and packaging, barcoding, and French labeling and packaging. The company offers genomic services that include nucleic acid extraction, DNA extraction, RNA extraction, SNP genotyping, PCR-based assays, whole genome and targeted sequencing, array-based SNP and expression profiling, custom assay development, and bioinformatic analysis, as well as support, analysis, and reporting. DNA Genotek Inc. offers its services in the areas of human genomics, including academic research, and clinical diagnostics, micribiome, infectious diseases, biobanking, animal genetics, and HLA typing through sales representatives or service coordinators worldwide. The company was founded in 1998 and is based in Ottawa, Canada. DNA Genotek Inc. operates as a subsidiary of OraSure Technologies, Inc.

Financial Information (Currency: CAD, in mm) 
Total Revenue
14.3
EBITDA
0.1
EBIT
(0.3)
Cash & ST Invst.
5.9
Net Income
(0.5)
Total Debt
0.0
Capital Expenditure
(0.2)
Total Assets
10.3


U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
Currency in CAD in mm, LTM as of Jun-30-2011 TEV and Market Cap are calculated using the last closing price

Key Professionals
Name
Title
Curry, Ian 
President
Birnboim, H. Chaim
Founder and Chief Scientific Officer
Walsh, Patrick
Chief Financial Officer
Fullerton, Dan
Vice President of Operations, Quality and Regulatory Affairs
MacCullough, Cindy
Vice President of Marketing
Michels, Douglas A.
Chief Executive Officer of Orasure Technologies and President of Orasure Technologies


Primary Industry Classification
Health Care Supplies


Primary Office Location
3000 - 500 Palladium Drive | Ottawa, ON | K2V 1C2 | Canada
Phone: 613-723-5757   Fax: 613-723-5057

Parent Company
OraSure Technologies, Inc. (NasdaqGS:OSUR)

Prior Investors
Band of Scoundrels, Purple Angel


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
CoreBiome, Inc.
CoreBiome, Inc. develops an artificial intelligence-based analytics platform that offers microbiome analysis using genomics and informatics. The company offers BoosterShot, an alternative to amplicon sequencing for large-scale microbiome experimentation; and BenchMark that helps design studies, collect samples, generate sequencing data, and analyze data using machine learning. It uses ultra-shallow shotgun sequencing to generate taxonomic and functional profiles of the microbiome with species-level resolution. The company combines sample processing and DNA sequencing with machine learning. The company also provides Core Analysis, which is a full primary data analysis and annotation, including closed-reference operational taxonomic unit (OTU) tables, genus-level taxonomy, species-level taxonomy where available, KEGG metabolic pathway and module tables predicted using the PICRUSt tool2, beta diversity analyses (genus-level Bray-Curtis distances, OTU-level weighted, and unweighted UniFrac distances), and alpha diversity analysis (Shannon, Simpson, Chao1, and whole-tree phylogenetic diversity). CoreBiome, Inc. was formerly known as Micrometer Genomics, Inc. The company was incorporated in 2016 and is based in Saint Paul, Minnesota. As of January 4, 2019, CoreBiome, Inc. operates as a subsidiary of DNA Genotek Inc.

United States and Canada
Life Sciences Tools and Services
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jan-04-2019
Jan-04-2019
Merger/Acquisition
Buyer
CoreBiome, Inc.
DNA Genotek Inc.

-
Jul-25-2011
Aug-17-2011
Merger/Acquisition
Target
DNA Genotek Inc.
OraSure Technologies, Inc. (NasdaqGS:OSUR)
Purple Angel
53.14
Dec-31-2001
Dec-31-2001
Private Placement
Target
DNA Genotek Inc.
Purple Angel

0.88
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Apr-07-2022
Product-Related Announcements
OraSure Technologies’ Subsidiary DNA Genotek Launches the First Device with De Novo Authorization from the FDA for the Preservation and Stabilization of Microbiome Samples
Jan-29-2021
Product-Related Announcements
DNA Genotek’s OMNIgene®·ORAL Included in EUA Granted to Ambry Genetics for Use in COVID-19 RT-PCR Saliva Test
Jan-28-2021
Product-Related Announcements
DNA Genotek’s OMNIgene ·ORAL Saliva Collection Device Receives Health Canada Authorization for Use in COVID-19 Testing
Sep-15-2020
Client Announcements
DNA Genotek and Diversigen Partner with Pure Culture Beauty to Provide OMNIgene·Skin Microbiome Collection Kits and Full Microbiome Analysis Services
Jun-17-2020
Client Announcements
Metabolon, Inc. and DNA Genotek Collaborate on First Ambient-Temperature Microbiome Sampling Solution for Metabolomics

M&A Advisors
Gowling WLG International Limited, Moelis Asset Management LP, Raymond James & Associates, Inc.


Advisors
Most Recent Auditor
Deloitte & Touche LLP
M&A Advisors
Gowling WLG International Limited, Moelis Asset Management LP, Raymond James & Associates, Inc.


Most Recent Auditor
Deloitte & Touche LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 09:12 PM
DNA Genotek Inc.
DNA Genotek Inc
Reports
34
GlobalData

Jun 15, 2023 06:18 AM
DNA Genotek Inc.
DNA Genotek Inc
Reports
34
GlobalData

Mar 14, 2023 01:31 AM
DNA Genotek Inc.
DNA Genotek Inc
Reports
34
GlobalData

Dec 16, 2022 02:45 AM
DNA Genotek Inc.
DNA Genotek Inc
Reports
34
GlobalData

Sep 21, 2022 06:30 AM
DNA Genotek Inc.
DNA Genotek Inc
Reports
34
GlobalData

Jun 20, 2022 04:12 AM
DNA Genotek Inc.
DNA Genotek Inc
Reports
33
GlobalData

Mar 17, 2022 03:05 AM
DNA Genotek Inc.
DNA Genotek Inc
Reports
33
GlobalData

Dec 14, 2021 01:28 AM
DNA Genotek Inc.
DNA Genotek Inc
Reports
21
GlobalData

Sep 13, 2021 05:39 AM
DNA Genotek Inc.
DNA Genotek Inc
Reports
15
GlobalData

Jun 15, 2021 08:21 PM
DNA Genotek Inc.
DNA Genotek Inc
Reports
15


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Colli-Pee, Laboratory and Analytical Services, Laboratory and Analytics Services, OMNIgene DISCOVER, OMNIgene·ORAL (Future), ORAcollect·RNA (Future), Oragene


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Dec-27-2018
Dec-27-2018
DNA Genotek Inc.
SEC
8-K (5.02, 9.01)
129 KB
Mar-29-2018
May-08-2018
OraSure Technologies, Inc. (NasdaqGS:OSUR)
SEC
DEF 14A
3 MB
Aug-05-2015
Aug-05-2015
OraSure Technologies, Inc. (NasdaqGS:OSUR)
SEC
8-K (2.02, 7.01, 9.01)
206 KB

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Curry, Ian 
President
613-723-5757
613-723-5057

Birnboim, H. Chaim
Founder and Chief Scientific Officer
613-723-5757
613-723-5057
-
Walsh, Patrick
Chief Financial Officer
613-723-5757
613-723-5057
-
Fullerton, Dan
Vice President of Operations, Quality and Regulatory Affairs
613-723-5757
613-723-5057
-
MacCullough, Cindy
Vice President of Marketing
613-723-5757
613-723-5057
-
Michels, Douglas A.
Chief Executive Officer of Orasure Technologies and President of Orasure Technologies
613-723-5757
613-723-5057

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
